WHO Prioritizes Next-Generation Filovirus Vaccines for Bundibugyo and Sudan Ebola Outbreak Trials

The Antigenic Blind Spot of First-Generation Zaire Ebola Vaccines

Over the past decade, emergency deployment of the licensed recombinant vesicular stomatitis virus vaccine Ervebo (rVSV-ZEBOV-GP) and the heterologous two-dose regimen Zabdeno/Mvabea (Ad26.ZEBOV + MVA-BN-Filo) transformed the containment of classical Ebola virus disease caused by Orthoebolavirus zairense (EBOV), achieving 97.5% ring-vaccination efficacy during epidemics in West Africa and the Democratic Republic of the Congo (DRC). However, the genus Orthoebolavirus (family Filoviridae) encompasses multiple antigenically distinct species that periodically spill over from chiropteran reservoir hosts into human populations: most notably Orthoebolavirus bundibugyoense (Bundibugyo virus, BDBV)—first identified in western Uganda in 2007 with case fatality rates of 25% to 51%—and Orthoebolavirus sudanense (Sudan virus, SUDV), which carries a historical case fatality rate of 41% to 65%.

The trimeric surface glycoprotein (GP_1,2) is the sole viral envelope protein mediating attachment and endosomal membrane fusion via the host late-endosomal cholesterol transporter Niemann-Pick C1 (NPC1). Across Orthoebolavirus species, GP_1,2 diverges by 35% to 45% at the amino acid level, with variation concentrated in the heavily glycosylated outer glycan cap and mucin-like domain (MLD) that shield the conserved receptor-binding site prior to endosomal cathepsin B/L proteolysis. Consequently, neutralizing Immunoglobulin G (IgG) antibodies elicited by monovalent Zaire ebolavirus Ervebo fail to cross-neutralize either Bundibugyo virus or Sudan virus in vivo.

The Tumaini and TOKEMEZA Intra-Outbreak Clinical Trial Frameworks

To close this antigenic gap during active filovirus spillovers, the World Health Organization (WHO) independent Technical Advisory Group on Candidate Vaccine Prioritization has backed the integration of two species-specific Bundibugyo vaccine candidates into the ongoing Tumaini clinical trial in the DRC—spearheaded by the Institut National de Recherche Biomédicale (INRB) in collaboration with Africa CDC, CEPI, and Médecins Sans Frontières (MSF):

• ChAdOx1 BDBV and ChAdOx1-BiEBOV (University of Oxford / Serum Institute of India): Replication-deficient simian adenovirus vector platforms encoding full-length filovirus GP_1,2 antigens, engineered to induce both rapid humoral neutralizing titers and CD8⁺ cytotoxic T-cell responses without pre-existing human anti-adenovirus-5 immunity.
• mRNA-1469 (Moderna): A nucleoside-modified lipid-nanoparticle (LNP) messenger RNA vaccine encoding native-like trimeric Bundibugyo GP_1,2, designed to drive high-titer germinal-center B-cell affinity maturation and Fc-mediated opsonophagocytic clearance.

This expansion directly parallels the TOKEMEZA SVD intra-outbreak ring-vaccination protocol launched in Uganda at the Makerere University Lung Institute within just four days of Sudan virus disease notification, which deployed the International AIDS Vaccine Initiative (IAVI) live-attenuated rVSV-SUDV vector alongside the Sabin Vaccine Institute's chimpanzee adenovirus candidate ChAd3-EBO-S.

Comparative Telemetry of Priority Non-Zaire Orthoebolavirus Vaccine Candidates

Ring Vaccination Kinetics and Basic Reproduction Number Suppression

Because non-Zaire filovirus outbreaks are sporadic and geographically focal (typically 20 to 200 cases per spillover event), traditional randomized placebo-controlled Phase 3 trials involving tens of thousands of unexposed volunteers cannot accumulate sufficient case endpoints. Instead, WHO's pre-positioned Core Protocol utilizes a cluster-randomized ring vaccination design modeled on the 2015 Guinea Ebola ça Suffit! trial. Immediately upon laboratory confirmation of an index case by reverse-transcription quantitative polymerase chain reaction (RT-qPCR), field epidemiologists trace all primary contacts and secondary contacts-of-contacts (forming an epidemiological ring of ~50–100 individuals) and randomize rings to immediate versus delayed (21-day) vaccination. By immunizing rings within a 4-to-7-day operational window—shorter than the 8-to-12-day mean incubation period of filoviral hemorrhagic fever—species-matched vaccines drive the effective reproduction number R_e below the epidemic threshold of 1.0 while simultaneously generating licensure-grade vaccine efficacy data during a single outbreak.